Praxis Precision Medicines (PRAX) is approaching two major FDA regulatory decisions, drawing increased analyst attention. JPMorgan raised its price target to $725, while B. Riley initiated coverage with a $713 price target, citing the potential impact of two upcoming drug decisions. 🔹 Key Highlights JPMorgan: Raised its PRAX price target to $725. B. Riley: Initiated coverage with a $713 price target. First FDA Decision: Relutrigine (PRAX-562), being developed for SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs). Relutrigine PDUFA: December 27, 2026. Second FDA Decision: Ulixacaltamide (PRAX-628), being developed for essential tremor. Ulixacaltamide PDUFA: January 29, 2027. Regulatory Updates: FDA mid-cycle reviews have reportedly identified no major safety or efficacy concerns to date, according to the supplied update. 💡 Why It Matters Praxis has two important regulatory milestones approaching within approximately ten weeks, creating potential near-term catalysts for the company. Positive FDA decisions could significantly influence the commercial outlook for both drug candidates. However, analyst price targets are estimates rather than guaranteed outcomes, and FDA approval is not assured until the agency completes its reviews. 🚀 Start Your 7-Day FREE ThinkSabio Trial https://www.thinksabio.com/ ThinkSabio — Stocks Simplified